Business Context and Reporting Period
This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. on June 22, 2023. The filing addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market under the trading symbol VTGN.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a compliance event regarding the company's stock price.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Event: The Nasdaq Listing Qualifications Staff determined the Company is in full compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Condition Met: The closing bid price of the Company's common stock exceeded $1.00 per share for the previous 10 consecutive trading days.
- Status: All previously outstanding deficiencies have been resolved, and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies. It confirms the removal of a specific regulatory risk related to delisting due to low stock price.
Investor Verification Checklist
- Verify the current trading price of VTGN to ensure it remains above the $1.00 threshold.
- Review the attached press release (Exhibit 99.1) for any additional context on the stock price recovery.
- Check subsequent filings for any new Nasdaq deficiency notices or other regulatory communications.